Table 2.
2-Way ANOVAs assessing (A) the interaction between obesity and co-morbid conditions on coronary dilations and (B) the interaction between obesity and commonly prescribed medications on coronary dilations
| A | ||
|---|---|---|
|
Interaction with obesity |
F test |
P value |
| Diabetes |
0.043 |
0.836 |
| Hypertension |
0.587 |
0.447 |
| Coronary artery disease |
1.714 |
0.195 |
| Hypercholesterolemia |
3.634 |
0.061 |
| Coronary artery bypass grafting |
0.023 |
0.880 |
| Aortic valve replacement |
0.033 |
0.856 |
|
B |
|
|
|
Interactions with obesity |
F test |
P value |
| ACE - Inhibitor |
7.469 |
0.008 |
| Angiotensin receptor blocker |
3.801 |
0.056 |
| Aspirin |
0.081 |
0.777 |
| Statin |
3.923 |
0.052 |
| Insulin |
2.196 |
0.144 |
| Oral anti-diabetic drug |
0.186 |
0.668 |
| Beta blocker |
7.581 |
0.008 |
| Diuretic |
1.513 |
0.224 |
| Calcium channel blocker |
0.904 |
0.345 |
| H+ blocker |
0.449 |
0.505 |
| Nitrate | 0.864 | 0.356 |
ACE – angiotensin converting enzyme inhibitor, Degrees of freedom and the error of degrees of freedom all have values of 1 and 60, respectively.